AIM: To examine the underlying mechanisms of erlotinib-induced growth inhibition in
hepatocellular carcinoma (HCC). METHODS: Erlotinib-induced alterations in gene …

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. In light of the very poor 5-year-survival new therapeutic …

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. Due to very poor 5-year-survival new therapeutic …

Background The transforming growth factor-α (TGF-α)/epidermal growth factor receptor
(EGFR) signaling pathway has been demonstrated to have a pivotal role in …

AIM: To investigate the effect and mechanism of action of erlotinib, an epidermal growth
factor receptor (EGFR) small molecule tyrosine kinase inhibitor (TKI), in the human …

BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor
(EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine …

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1
(EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs) …

Erlotinib is a small-molecular inhibitor of epidermal growth factor receptor (EGFR). Here, we
identify that cancerous inhibitor of protein phosphatase 2A (CIP2A) is a major determinant …

Epidermal growth factor receptor (EGFR)‐and type 1 insulin‐like growth factor receptor (IGF‐
1R)‐dependent pathways are up‐regulated in hepatocellular carcinoma (HCC), and cross …

Erlotinib, an EGFR tyrosine kinase inhibitor has been introduced into cancer chemotherapy.
However, the therapeutic effects of erlotinib in hepatocellular carcinoma (HCC) remain …